Pheochromocytoma Market Research Report - Global Forecast till 2027

Global Pheochromocytoma Market Research Report: By Treatment Type (Alpha-Blockers, Beta Blockers, Surgery, Radionuclide Treatment, Others) and By End-User (Hospitals and Clinics, Research and Academic Institutes, Others) – Forecast to 2027

ID: MRFR/HC/7084-HCR | February, 2021 | Region : Global

Market Forecast


Pheochromocytoma Market accounted for a value of USD 2,814.75 Million in 2018 at a CAGR of 3.84%.


Market Synopsis


Pheochromocytoma is a rare type of hormone-secreting tumor that develops in the adrenal gland. Approximately 5% of all adrenal gland tumors are pheochromocytoma. The tumor is usually benign and hence does not cause cancer in most of the cases. Only 10% of the pheochromocytomas have chances to become cancerous. This adrenal gland tumor secretes the catecholamine hormones that may cause either episodic or persistent high blood pressure. The condition is similar to adrenal paraganglioma. It arises from the chromaffin cells. Approximately 25% to 35% of cases of pheochromocytoma can be due to genetic disruptions or mutations to certain genes. The rising prevalence of pheochromocytoma and increase research and development for the development of specific treatment options for the condition is expected to drive the market growth. The incidence rate of pheochromocytoma is 2 to 8 million people per year worldwide. Moreover, increasing the number of drugs in the clinical trials is also anticipated to fuel the market growth. Cabozantinib, Sunitinib, Lenvatinib, Lutathera and ONC 201 are some of the drugs which are clinical trials for use in the treatment of pheochromocytoma.


Market Influencer


An increasing number of drugs in the clinical trials are positively influencing the market growth. These drugs are cabozantinib by Exelixis, Inc., zebra by Progenics Pharmaceuticals, Inc., and Lutathera by Advanced Accelerator Applications, among others.


Market Drivers



  • Increasing investment by major companies to develop specific treatment options

  • High prevalence of pheochromocytoma

  • The growing number of clinical trials for drugs to treat pheochromocytoma

  • Rapidly changing lifestyle

  • Rising healthcare expenditure

  • Increasing incidence rate of rare tumors


Market Restraints



  • Stringent government regulations

  • Lack of availability of specific medications

  • Lack of awareness related to the disease


Segmentation


By Treatment Type



  • Alpha-Blockers: These are used to relax the small arteries and veins, hence improving blood flow and decreasing the blood pressure.



  • Beta Blockers: These are used for the reduction of blood pressure. Beta-blockers are administered in combination with alpha-blockers.



  • Surgery: Segment that holds the largest market share. In most of the cases, the entire adrenal gland which has pheochromocytoma is removed using a laparoscopic surgery or other minimally invasive surgery techniques. The other adrenal glands have the capability to carry out the normal function.



  • Radionuclide Treatment: This treatment combines a type of radioactive iodine with MIBG, a compound that attaches to the adrenal tumor. With this, the radiation therapy reaches to the specific site and kills the cancerous cell. The radionuclide treatment segment is expected to demonstrate the fastest growth owing to its increasing adoption to treat cancer.



  • Others: Other treatment options include chemotherapy and other targeted cancer therapies. These are used only if the tumor becomes cancerous.


By End-User



  • Hospitals and Clinics: The largest segment as it is the primary point of care for the treatment of the diseases.



  • Research and Academic Institutes: The fastest-growing segment owing to the rising research and development activities for the development of better treatment options for pheochromocytoma.



  • Others: Other end-users in the pheochromocytoma market include ambulatory surgical centers and centers for the treatment of cancer.


By Region



  • Americas: is the largest regional market. The incidence rate of pheochromocytoma is high in the Americas. Every year approximately, 1000 new cases of pheochromocytoma are diagnosed in the US. Moreover, the presence of significant pharmaceutical companies such as Pfizer, Inc., Jubilant Cadista, Mylan N.V., and Exelixis, Inc. is expected to drive the market growth. The rising number of technological advancements in the Americas and the availability of cost-effective treatment options are expected to drive market growth.



  • Europe: The pheochromocytoma market in Europe is expected to slowly grow owing to the moderate prevalence of the rare type of tumors including pheochromocytoma in the European region. As of June 2018, 1 in 100,000 people in the UK are diagnosed with pheochromocytoma every year.



  • Asia-Pacific: It is the fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people suffering from adrenal gland tumors that includes pheochromocytoma. Moreover, the developing healthcare infrastructure is also expected to drive the market growth.



  • Middle East & Africa: The market is expected to show significant growth due to the rising patient population suffering from various types of tumors.


Key Players



  • Pfizer Inc. (US)

  • Teva Pharmaceutical Company Limited (Israel)

  • Zydus Cadila (India)

  • Novartis AG (Switzerland)

  • Curium Pharma (UK)

  • Jubilant Cadista (US)

  • AstraZeneca (UK)

  • Mylan N.V. (US)

  • Apotex Inc. (Canada)

  • Reddy’s Laboratories Ltd (India)

  • Lupin (India)

  • Glenmark Pharmaceuticals Limited (India)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Pipeline Analysis


6. GLOBAL PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE

6.1. Overview

6.2. Alpha-Blockers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Beta-Blockers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Surgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Radionuclide Treatment

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL PHEOCHROMOCYTOMA MARKET, BY END USER

7.1. Overview

7.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL PHEOCHROMOCYTOMA MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Pheochromocytoma Market

9.5. Competitive Benchmarking

9.6. Leading Players in terms of Number of Developments in the Global Pheochromocytoma Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2020

9.8.2. Major Players R&D Expenditure 2020

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Pfizer, Inc.

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Teva Pharmaceuticals Company Limited

10.2.1. Company Overview

10.2.2. Product Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Zydus Cadila

10.3.1. Company Overview

10.3.2. Product Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Novartis AG

10.4.1. Company Overview

10.4.2. Product Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Curium Pharma

10.5.1. Company Overview

10.5.2. Product Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Jubilant Cadista

10.6.1. Company Overview

10.6.2. Product Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. AstraZeneca

10.7.1. Company Overview

10.7.2. Product Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Mylan N.V.

10.8.1. Company Overview

10.8.2. Product Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Apotex Inc.

10.9.1. Company Overview

10.9.2. Product Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Dr. Reddy’s Laboratories Ltd

10.10.1. Company Overview

10.10.2. Product Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Lupin

10.11.1. Company Overview

10.11.2. Product Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Glenmark Pharmaceuticals Limited

10.12.1. Company Overview

10.12.2. Product Overview

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

10.13. Others

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL PHEOCHROMOCYTOMA MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL PHEOCHROMOCYTOMA MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)

TABLE 3 GLOBAL PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 4 GLOBAL PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 5 GLOBAL PHEOCHROMOCYTOMA MARKET, BY REGION, 2020-2027(USD MILLION)

TABLE 6 NORTH AMERICA: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 7 NORTH AMERICA: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 8 US: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 9 US: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 CANADA: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 11 CANADA: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 12 LATIN AMERICA: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 13 LATIN AMERICA: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 14 EUROPE: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 15 EUROPE: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 WESTERN EUROPE: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 17 WESTERN EUROPE: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 18 EASTERN EUROPE: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 19 EASTERN EUROPE: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 20 ASIA-PACIFIC: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 21 ASIA-PACIFIC: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: PHEOCHROMOCYTOMA MARKET, BY TREATMENT TYPE, 2020-2027(USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: PHEOCHROMOCYTOMA MARKET, BY END USER, 2020-2027(USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PHEOCHROMOCYTOMA MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PHEOCHROMOCYTOMA MARKET

FIGURE 4 GLOBAL PHEOCHROMOCYTOMA MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 5 GLOBAL PHEOCHROMOCYTOMA MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL PHEOCHROMOCYTOMA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: PHEOCHROMOCYTOMA MARKET SHARE BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: PHEOCHROMOCYTOMA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 8 EUROPE: PHEOCHROMOCYTOMA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 WESTERN EUROPE: PHEOCHROMOCYTOMA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 ASIA-PACIFIC: PHEOCHROMOCYTOMA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 MIDDLE EAST & AFRICA: PHEOCHROMOCYTOMA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 GLOBAL PHEOCHROMOCYTOMA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 PFIZER, INC..: KEY FINANCIALS

FIGURE 14 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 15 PFIZER, INC.: REGIONAL REVENUE

FIGURE 16 TEVA PHARMACEUTICALS COMPANY LIMITED: KEY FINANCIALS

FIGURE 17 TEVA PHARMACEUTICALS COMPANY LIMITED: SEGMENTAL REVENUE

FIGURE 18 TEVA PHARMACEUTICALS COMPANY LIMITED: REGIONAL REVENUE

FIGURE 19 ZYDUS CADILA: KEY FINANCIALS

FIGURE 20 ZYDUS CADILA: SEGMENTAL REVENUE

FIGURE 21 ZYDUS CADILA: REGIONAL REVENUE

FIGURE 22 NOVARTIS AG: KEY FINANCIALS

FIGURE 23 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 24 NOVARTIS AG: REGIONAL REVENUE

FIGURE 25 CURIUM PHARMA: KEY FINANCIALS

FIGURE 26 CURIUM PHARMA: SEGMENTAL REVENUE

FIGURE 27 CURIUM PHARMA: REGIONAL REVENUE

FIGURE 28 JUBILANT CADISTA: KEY FINANCIALS

FIGURE 29 JUBILANT CADISTA: SEGMENTAL REVENUE

FIGURE 30 JUBILANT CADISTA: REGIONAL REVENUE

FIGURE 31 ASTRAZENECA: KEY FINANCIALS

FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 33 ASTRAZENECA: REGIONAL REVENUE

FIGURE 34 MYLAN N.V.: KEY FINANCIALS

FIGURE 35 MYLAN N.V.: SEGMENTAL REVENUE

FIGURE 36 MYLAN N.V.: REGIONAL REVENUE

FIGURE 37 APOTEX INC.: KEY FINANCIALS

FIGURE 38 APOTEX INC.: SEGMENTAL REVENUE

FIGURE 39 APOTEX INC.: REGIONAL REVENUE

FIGURE 40 DR. REDDY’S LABORATORIES LTD: KEY FINANCIALS

FIGURE 41 DR. REDDY’S LABORATORIES LTD: SEGMENTAL REVENUE

FIGURE 42 DR. REDDY’S LABORATORIES LTD: REGIONAL REVENUE

FIGURE 43 LUPIN: KEY FINANCIALS

FIGURE 44 LUPIN: SEGMENTAL REVENUE

FIGURE 45 LUPIN: REGIONAL REVENUE

FIGURE 46 GLENMARK PHARMACEUTICALS LIMITED: KEY FINANCIALS

FIGURE 47 GLENMARK PHARMACEUTICALS LIMITED: SEGMENTAL REVENUE

FIGURE 48 GLENMARK PHARMACEUTICALS LIMITED: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Pheochromocytoma Market